Pre-Exposure Prophylaxis (PrEP) is a preventive medical strategy for individuals at high risk of contracting HIV, involving the use of antiretroviral medication to significantly reduce the likelihood of infection. When taken consistently, PrEP can lower the risk of HIV transmission by up to 99% in high-risk populations, such as men who have sex with men and heterosexual couples with an HIV-positive partner. PrEP typically includes medications like tenofovir disoproxil fumarate and emtricitabine, taken orally on a daily basis or as directed by a healthcare provider.
The global Pre-Exposure Prophylaxis (PrEP) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pre-Exposure Prophylaxis (PrEP) include Gilead Sciences, ViiV Healthcare, Teva, Amneal Pharmaceuticals, Aurobindo Pharma, Mylan, Zydus, Qilu Pharmaceutical, Anhui Baker Biopharmaceutical, Chengdu Brilliant Pharmaceutical, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pre-Exposure Prophylaxis (PrEP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pre-Exposure Prophylaxis (PrEP).
The Pre-Exposure Prophylaxis (PrEP) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Pre-Exposure Prophylaxis (PrEP) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pre-Exposure Prophylaxis (PrEP) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Segment by Type
Oral PrEP
Injectable PrEP
Segment by Application
Hospital and Clinic
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pre-Exposure Prophylaxis (PrEP) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pre-Exposure Prophylaxis (PrEP) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.鈥�
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Pre-Exposure Prophylaxis (PrEP) Market Overview
1.1 Product Definition
1.2 Pre-Exposure Prophylaxis (PrEP) by Type
1.2.1 Global Pre-Exposure Prophylaxis (PrEP) Market Value Comparison by Type (2024-2030)
1.2.2 Oral PrEP
1.2.3 Injectable PrEP
1.3 Pre-Exposure Prophylaxis (PrEP) by Application
1.3.1 Global Pre-Exposure Prophylaxis (PrEP) Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Pre-Exposure Prophylaxis (PrEP) Market Size Estimates and Forecasts
1.4.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue 2019-2030
1.4.2 Global Pre-Exposure Prophylaxis (PrEP) Sales 2019-2030
1.4.3 Global Pre-Exposure Prophylaxis (PrEP) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pre-Exposure Prophylaxis (PrEP) Market Competition by Manufacturers
2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pre-Exposure Prophylaxis (PrEP) Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Pre-Exposure Prophylaxis (PrEP), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pre-Exposure Prophylaxis (PrEP), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pre-Exposure Prophylaxis (PrEP), Product Type & Application
2.7 Global Key Manufacturers of Pre-Exposure Prophylaxis (PrEP), Date of Enter into This Industry
2.8 Global Pre-Exposure Prophylaxis (PrEP) Market Competitive Situation and Trends
2.8.1 Global Pre-Exposure Prophylaxis (PrEP) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Pre-Exposure Prophylaxis (PrEP) Players Market Share by Revenue
2.8.3 Global Pre-Exposure Prophylaxis (PrEP) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pre-Exposure Prophylaxis (PrEP) Market Scenario by Region
3.1 Global Pre-Exposure Prophylaxis (PrEP) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region: 2019-2030
3.2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region: 2019-2024
3.2.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region: 2025-2030
3.3 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region: 2019-2030
3.3.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region: 2019-2024
3.3.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Region: 2025-2030
3.4 North America Pre-Exposure Prophylaxis (PrEP) Market Facts & Figures by Country
3.4.1 North America Pre-Exposure Prophylaxis (PrEP) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pre-Exposure Prophylaxis (PrEP) Sales by Country (2019-2030)
3.4.3 North America Pre-Exposure Prophylaxis (PrEP) Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pre-Exposure Prophylaxis (PrEP) Market Facts & Figures by Country
3.5.1 Europe Pre-Exposure Prophylaxis (PrEP) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pre-Exposure Prophylaxis (PrEP) Sales by Country (2019-2030)
3.5.3 Europe Pre-Exposure Prophylaxis (PrEP) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pre-Exposure Prophylaxis (PrEP) Market Facts & Figures by Region
3.6.1 Asia Pacific Pre-Exposure Prophylaxis (PrEP) Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pre-Exposure Prophylaxis (PrEP) Sales by Region (2019-2030)
3.6.3 Asia Pacific Pre-Exposure Prophylaxis (PrEP) Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Pre-Exposure Prophylaxis (PrEP) Market Facts & Figures by Country
3.7.1 Latin America Pre-Exposure Prophylaxis (PrEP) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pre-Exposure Prophylaxis (PrEP) Sales by Country (2019-2030)
3.7.3 Latin America Pre-Exposure Prophylaxis (PrEP) Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Market Facts & Figures by Country
3.8.1 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pre-Exposure Prophylaxis (PrEP) Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2019-2030)
4.1.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2019-2024)
4.1.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Type (2025-2030)
4.1.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Type (2019-2030)
4.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2019-2030)
4.2.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2019-2024)
4.2.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Type (2025-2030)
4.2.3 Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Type (2019-2030)
4.3 Global Pre-Exposure Prophylaxis (PrEP) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2019-2030)
5.1.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2019-2024)
5.1.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Application (2025-2030)
5.1.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Market Share by Application (2019-2030)
5.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2019-2030)
5.2.1 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2019-2024)
5.2.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Application (2025-2030)
5.2.3 Global Pre-Exposure Prophylaxis (PrEP) Revenue Market Share by Application (2019-2030)
5.3 Global Pre-Exposure Prophylaxis (PrEP) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Teva
6.3.1 Teva Company Information
6.3.2 Teva Description and Business Overview
6.3.3 Teva Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Teva Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.3.5 Teva Recent Developments/Updates
6.4 Amneal Pharmaceuticals
6.4.1 Amneal Pharmaceuticals Company Information
6.4.2 Amneal Pharmaceuticals Description and Business Overview
6.4.3 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.4.5 Amneal Pharmaceuticals Recent Developments/Updates
6.5 Aurobindo Pharma
6.5.1 Aurobindo Pharma Company Information
6.5.2 Aurobindo Pharma Description and Business Overview
6.5.3 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.5.5 Aurobindo Pharma Recent Developments/Updates
6.6 Mylan
6.6.1 Mylan Company Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Mylan Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.6.5 Mylan Recent Developments/Updates
6.7 Zydus
6.7.1 Zydus Company Information
6.7.2 Zydus Description and Business Overview
6.7.3 Zydus Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Zydus Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.7.5 Zydus Recent Developments/Updates
6.8 Qilu Pharmaceutical
6.8.1 Qilu Pharmaceutical Company Information
6.8.2 Qilu Pharmaceutical Description and Business Overview
6.8.3 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.8.5 Qilu Pharmaceutical Recent Developments/Updates
6.9 Anhui Baker Biopharmaceutical
6.9.1 Anhui Baker Biopharmaceutical Company Information
6.9.2 Anhui Baker Biopharmaceutical Description and Business Overview
6.9.3 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.9.5 Anhui Baker Biopharmaceutical Recent Developments/Updates
6.10 Chengdu Brilliant Pharmaceutical
6.10.1 Chengdu Brilliant Pharmaceutical Company Information
6.10.2 Chengdu Brilliant Pharmaceutical Description and Business Overview
6.10.3 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.10.5 Chengdu Brilliant Pharmaceutical Recent Developments/Updates
6.11 North China Pharmaceutical
6.11.1 North China Pharmaceutical Company Information
6.11.2 North China Pharmaceutical Description and Business Overview
6.11.3 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.11.5 North China Pharmaceutical Recent Developments/Updates
6.12 Chia Tai Tianqing Pharmaceutical
6.12.1 Chia Tai Tianqing Pharmaceutical Company Information
6.12.2 Chia Tai Tianqing Pharmaceutical Description and Business Overview
6.12.3 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
6.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pre-Exposure Prophylaxis (PrEP) Industry Chain Analysis
7.2 Pre-Exposure Prophylaxis (PrEP) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pre-Exposure Prophylaxis (PrEP) Production Mode & Process
7.4 Pre-Exposure Prophylaxis (PrEP) Sales and Marketing
7.4.1 Pre-Exposure Prophylaxis (PrEP) Sales Channels
7.4.2 Pre-Exposure Prophylaxis (PrEP) Distributors
7.5 Pre-Exposure Prophylaxis (PrEP) Customers
8 Pre-Exposure Prophylaxis (PrEP) Market Dynamics
8.1 Pre-Exposure Prophylaxis (PrEP) Industry Trends
8.2 Pre-Exposure Prophylaxis (PrEP) Market Drivers
8.3 Pre-Exposure Prophylaxis (PrEP) Market Challenges
8.4 Pre-Exposure Prophylaxis (PrEP) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Gilead Sciences
ViiV Healthcare
Teva
Amneal Pharmaceuticals
Aurobindo Pharma
Mylan
Zydus
Qilu Pharmaceutical
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Chia Tai Tianqing Pharmaceutical
听
听
*If Applicable.